Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.62 |
| ▸ | GRM5 | P41594 | 5/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12412112 | 0.89 | GRM5 (0.61) | CYP1A2CYP2C9GRM5CYP3A4SLC6A3 | |
| SCHEMBL12412715 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2C9GRM5KCNH2CYP3A4 | |
| SCHEMBL12412716 | 0.88 | GRM5 (0.53) | CYP1A2CYP2C9GRM5KCNH2CYP3A4 | |
| SCHEMBL12412155 | 0.87 | GRM5 (0.55) | CYP1A2CYP2C9GRM5KCNH2 | |
| SCHEMBL12416415 | 0.86 | CYP1A2 (0.64) | CYP1A2CYP2C9GRM5KCNH2CYP3A4 | |
| SCHEMBL12412459 | 0.86 | CYP1A2 (0.64) | CYP1A2CYP2C9GRM5KCNH2CYP3A4 | |
| SCHEMBL12412163 | 0.85 | GRM5 (0.48) | CYP1A2CYP2C9GRM5KCNH2 | |
| SCHEMBL12412719 | 0.85 | GRM5 (0.52) | CYP1A2CYP2C9GRM5KCNH2 | |
| SCHEMBL12412169 | 0.84 | GRM5 (0.56) | CYP1A2CYP2C9GRM5KCNH2CYP3A4 | |
| SCHEMBL12412111 | 0.84 | CYP3A4 (0.68) | CYP1A2CYP2C9GRM5KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | CYP1A2 3957/4885CYP2C9 3600/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.